Mit Page 357 and 358: Name Paper ref
GOLO Release is marketed as a food supplement , not an MHRA-licensed medicine
Furthermore, ongoing studies are exploring its potential cardiovascular and kidney benefits
Receptor Signaling: GPCRs and Beyond Butyrate activates several G-protein coupled receptors (GPCRs) that mediate its systemic effects: [7] GPR41 (FFAR3) Expressed in enteroendocrine cells, adipose tissue, and immune cells, GPR41 activation by butyrate: Stimulates GLP-1 and PYY secretion , regulating appetite and glucose metabolism Modulates adipocyte function and energy storage Influences sympathetic nervous system activity GPR43 (FFAR2) With broader expression including intestinal epithelium, immune cells, and adipocytes, GPR43 mediates: Promotes healthy inflammation responses through regulatory T cell (Treg) expansion Neutrophil chemotaxis and immune cell recruitment Insulin sensitivity improvements Intestinal barrier enhancement GPR109A (HCA2) This receptor, also known as the niacin receptor , responds to butyrate by: Supporting colonic immune balance and cellular resilience Inducing IL-18 production, which maintains epithelial integrity Promoting anti-inflammatory macrophage differentiation Immune Modulation: The Treg Connection One of butyrate's most important systemic effects involves regulatory T cell (Treg) differentiation
95,96 In addition, depletion of cystine and cysteine is also linked to the immunosuppressive effect of MDSCs
In 2025, venture investment is projected to reach $986 million on an annualized basis, underscoring the confidence investors have in the long-term profitability of this sector
.png)
